A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 143

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 143
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 209
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 994
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3134
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 574
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 488
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. | LitMetric

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.

N Engl J Med

From Dana-Farber Cancer Institute (J.A.C., J.A.M.), Boston Medical Center (M.H.K.), and Boston University (M.H.K.) - all in Boston; the Alliance Statistics and Data Management Center, Mayo Clinic (S.G., T.Z., S.P., F.-S.O.), and Mayo Clinic Comprehensive Cancer Center (T.R.H.) - both in Rochester, MN; Wright Center of Innovation and the Imaging and Radiation Oncology Core, University of Cincinnati, Cincinnati (M.V.K.), and the Ohio State University Comprehensive Cancer Center, Columbus (B.K.) - both in Ohio; the University of California, San Francisco, San Francisco (S.B.), and Stanford Cancer Center, Stanford (S.S.) - both in California; Alliance Statistics and Data Management Center, Mayo Clinic, Scottsdale, AZ (A.C.D.); the University of Hawaii Cancer Center, Honolulu (J.A.); the Alliance Protocol Operations Office, University of Chicago, Chicago (A.S.); Mount Sinai Medical Center (E.M.W.) and Memorial Sloan Kettering Cancer Center (N.R., E.M.O.) - both in New York; Washington University School of Medicine and Siteman Cancer Center, St. Louis (N.A.T.); the University of New Mexico Comprehensive Cancer Center, Albuquerque (B.T.); Fox Chase Cancer Center, Philadelphia (N.V.); M.D. Anderson Cancer Center, Houston (A.D.); Moffitt Cancer Center, Tampa, FL (J.R.S.); and the National Cancer Institute, Bethesda, MD (E.C.K.).

Published: September 2024

AI Article Synopsis

  • The study focused on the effectiveness of cabozantinib for treating advanced neuroendocrine tumors, comparing it to a placebo among previously treated patients.
  • In two independent patient groups (those with extrapancreatic and pancreatic neuroendocrine tumors), cabozantinib significantly increased median progression-free survival: 8.4 months for extrapancreatic and 13.8 months for pancreatic tumors compared to their respective placebo groups.
  • While cabozantinib showed better outcomes, it also resulted in a higher incidence of severe side effects (about 62-65%) compared to the placebo group (23-27%), with common issues including high blood pressure and fatigue.

Article Abstract

Background: Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear.

Methods: We enrolled two independent cohorts of patients - those with extrapancreatic neuroendocrine tumors and those with pancreatic neuroendocrine tumors - who had received peptide receptor radionuclide therapy or targeted therapy or both. Patients were randomly assigned in a 2:1 ratio to receive cabozantinib at a dose of 60 mg daily or placebo. The primary end point was progression-free survival as assessed by blinded independent central review. Key secondary end points included objective response, overall survival, and safety.

Results: In the cohort of 203 patients with extrapancreatic neuroendocrine tumors, the median progression-free survival with cabozantinib was 8.4 months, as compared with 3.9 months with placebo (stratified hazard ratio for progression or death, 0.38; 95% confidence interval [CI], 0.25 to 0.59; P<0.001). In the cohort of 95 patients with pancreatic neuroendocrine tumors, the median progression-free survival with cabozantinib was 13.8 months, as compared with 4.4 months with placebo (stratified hazard ratio, 0.23; 95% CI, 0.12 to 0.42; P<0.001). The incidence of confirmed objective response with cabozantinib was 5% and 19% among patients with extrapancreatic and pancreatic neuroendocrine tumors, respectively, as compared with 0% with placebo. Grade 3 or higher adverse events were noted in 62 to 65% of the patients treated with cabozantinib, as compared with 23 to 27% of the patients who received placebo. Common treatment-related adverse events of grade 3 or higher included hypertension, fatigue, diarrhea, and thromboembolic events.

Conclusions: Cabozantinib, as compared with placebo, significantly improved progression-free survival in patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors. Adverse events were consistent with the known safety profile of cabozantinib. (Funded by the National Cancer Institute and others; CABINET ClinicalTrials.gov number, NCT03375320.).

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2403991DOI Listing

Publication Analysis

Top Keywords

neuroendocrine tumors
24
advanced neuroendocrine
8
pancreatic neuroendocrine
8
patients extrapancreatic
8
extrapancreatic neuroendocrine
8
progression-free survival
8
neuroendocrine
6
tumors
6
phase trial
4
cabozantinib
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: